Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis

Tetiana Tatarchuka Department of Endocrine Gynaecology, National Institute of Pediatrics, Obstetrics and Gynecology of National Academy of Medical Science of Ukraine, Kyiv, UkraineView further author information

John C. Stevensonb National Heart and Lung Institute, Royal Brompton Hospital and Imperial College London, London, UKView further author information

Qi Yuc Gynecological Endocrinology and Reproductive Center, Peking Union Medical College Hospital, Beijing, ChinaView further author information

Elke Kahlerd Global Biometrics, Established Pharmaceuticals Division, Abbott Laboratories GmbH, Hannover, GermanView further author information

Marcelo Graziano Custodioe Global Innovation and Development, Established Pharmaceuticals Division, Abbott Products Operations AG, Allschwil, SwitzerlandCorrespondence[email protected]
View further author information

Mulan Renf Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing, ChinaView further author information

Rossella E. Nappig Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy;h Research Center for Reproductive Medicine and Gynecological Endocrinology – Menopause Unit, IRCCS S Matteo Foundation, Pavia, ItalyView further author information

Viktoriya Karpovai Established Pharmaceuticals Division, Abbott Ukraine LLC, Kyiv, UkraineView further author information

Tommaso Simoncinij Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyView further author information

show all

Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date